



China International Capital Corporation
Hong Kong Securities Limited

29/F One International Finance Centre
1 Harbour View Street
Central
Hong Kong

Date: December 13, 2022

PRIVATE AND CONFIDENTIAL

The Board of Directors
OrbusNeich Medical Group Holdings Limited
Units 303 & 305
3/F, Building 20E
Hong Kong Science Park
Shatin, N.T.
Hong Kong

Dear Sirs

Re: Consent to the Issue of the Prospectus of OrbusNeich Medical Group Holdings Limited 業聚醫療集團控股有限公司 (the “Company”) in connection with the Global Offering

We refer to the prospectus of the Company dated December 13, 2022 (the “Prospectus”) in connection with the global offering and the proposed listing of its shares of the Company on the Main Board of The Stock Exchange of Hong Kong Limited (the “Stock Exchange”).

We hereby give, and confirm that we have not withdrawn:

- i. our consent to the issue of the Prospectus and the inclusion therein of, and all references thereto, our name, our qualifications, our confirmations and opinions in the form and context in which they respectively appear in the Prospectus;
- ii. our consent to a statement of the aforesaid in the Prospectus; and
- iii. our consent to you releasing this letter to the Registrar of Companies in Hong Kong and the Stock Exchange for the purpose of the registration of the Prospectus.

We also hereby consent, and confirm that we have not withdrawn our consent, to a copy of this letter being made available on display as described in the Prospectus.

[The remainder of this page is intentionally left blank]

For and on behalf of
China International Capital Corporation Hong Kong Securities Limited



Name: Sin Tak Keung
Title: Executive Director

12/F CCB Tower
3 Connaught Road Central
Central
Hong Kong

Date: December 13, 2022

PRIVATE AND CONFIDENTIAL

The Board of Directors
OrbusNeich Medical Group Holdings Limited
Units 303 & 305
3/F, Building 20E
Hong Kong Science Park
Shatin, N.T.
Hong Kong

Dear Sirs

Re: Consent to the Issue of the Prospectus of OrbusNeich Medical Group Holdings Limited 業聚醫療集團控股有限公司 (the “Company”) in connection with the Global Offering

We refer to the prospectus of the Company dated December 13, 2022 (the “Prospectus”) in connection with the global offering and the proposed listing of its shares of the Company on the Main Board of The Stock Exchange of Hong Kong Limited (the “Stock Exchange”).

We hereby give, and confirm that we have not withdrawn:

- i. our consent to the issue of the Prospectus and the inclusion therein of, and all references thereto, our name, our qualifications, our confirmations and opinions in the form and context in which they respectively appear in the Prospectus;
- ii. our consent to a statement of the aforesaid in the Prospectus; and
- iii. our consent to you releasing this letter to the Registrar of Companies in Hong Kong and the Stock Exchange for the purpose of the registration of the Prospectus.

We also hereby consent, and confirm that we have not withdrawn our consent, to a copy of this letter being made available on display as described in the Prospectus.

[The remainder of this page is intentionally left blank]

For and on behalf of
CCB International Capital Limited




Name: Calvin Chan
Title: Managing Director

For and on behalf of
CCB International Capital Limited



Name: Robert Kong
Title: Director

For and on behalf of
CCB International Capital Limited

A handwritten signature in blue ink, consisting of several loops and a long horizontal stroke extending to the right.

Name: Michelle Pan
Title: Managing Director



羅兵咸永道

The Board of Directors
OrbusNeich Medical Group Holdings Limited
Units 303 & 305, 3/F, Building 20E
Hong Kong Science Park
Shatin, N.T.
Hong Kong

13 December 2022

Our Ref: AKWL.GTKL/02087658.A002


Dear Sirs

We refer to the prospectus dated 13 December 2022 in connection with the proposed initial listing of shares of OrbusNeich Medical Group Holdings Limited (the "Company") on the Main Board of The Stock Exchange of Hong Kong Limited (the "Prospectus"), a copy of which is attached and initialled by us on its front cover for the purpose of identification.

Our engagement to prepare this letter has been performed in accordance with Hong Kong Standard on Investment Circular Reporting Engagements 200, *Accountants' Reports on Historical Financial Information in Investment Circulars* issued by the Hong Kong Institute of Certified Public Accountants.

We hereby consent to the inclusion of our accountant's report and our report on unaudited pro forma financial information, both dated 13 December 2022, in the Prospectus, and the references to our name in the form and context in which they are included.

Yours faithfully

A large, stylized handwritten signature in black ink, consisting of a series of loops and a long trailing line that extends downwards and to the right.

PricewaterhouseCoopers
Certified Public Accountants
Hong Kong

Date: December 13, 2022

OrbusNeich Medical Group Holdings Limited
業聚醫療集團控股有限公司

Units 303 & 305
3/F, Building 20E
Hong Kong Science Park
Shatin, N.T.
Hong Kong

Attention: The Board of Directors

Dear Sirs,

Consent to the issue of the Prospectus of OrbusNeich Medical Group Holdings Limited
業聚醫療集團控股有限公司 (the "Company")

We refer to the prospectus of the Company dated December 13, 2022 (the "**Prospectus**") in connection with the global offering and the proposed listing of the shares of the Company on the Main Board of The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**") (the "**Proposed Listing**").

As the legal advisors to the Company as to the PRC laws in relation to the Proposed Listing, we hereby give, and confirm we have not withdrawn, our consent to the issue of the Prospectus with the inclusion therein of, and all references thereto, our name, qualification, and our opinions, in the form and context in which they respectively appear in the Prospectus.

We hereby consent to you releasing this letter to the Registrar of Companies in Hong Kong and the Stock Exchange for the purpose of the registration of the Prospectus and referring to it in the Prospectus. We also hereby consent to a copy of this letter and our PRC legal opinions being on display as described in the Prospectus.

(signature page to follow)

*(signature page to expert consent letter in relation to
the proposed listing of OrbusNeich Medical Group Holdings Limited)*

Yours faithfully,

King & Wood Mallesons

King & Wood Mallesons

CONYERS

CONYERS DILL & PEARMAN

29th Floor
One Exchange Square
8 Connaught Place
Central
Hong Kong
T +852 2524 7106 | F +852 2845 9268
conyers.com

December 13, 2022

Matter No.: 834227/108104284
(852) 2842 9532/ (852) 2842 9580

Wynne.Lau@conyers.com / Ryan.McConvey@conyers.com

The Board of Directors

OrbusNeich Medical Group Holdings Limited (業聚醫療集團控股有限公司)

Units 303 & 305,
3/F, Building 20E,
Hong Kong Science Park,
Shatin, N.T.
Hong Kong

Dear Sirs,

Re: **OrbusNeich Medical Group Holdings Limited (業聚醫療集團控股有限公司) (the “Company”)**

We refer to the prospectus of the Company dated December 13, 2022 (the “**Prospectus**”) in connection with the global offering and the proposed listing of the shares of the Company on the Main Board of The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

We hereby give, and confirm we have not withdrawn, our consent to the issue of the Prospectus and the inclusion therein of, and all references thereto, our name, qualification and the summary of certain aspects of Cayman Islands company law, in the form and context in which they respectively appear in the Prospectus.

We hereby consent to you releasing this letter to the Registrar of Companies in Hong Kong and the Stock Exchange for the purpose of the registration of the Prospectus and referring to it in the Prospectus. We also hereby consent to a copy of this letter and our letter of advice summarising certain aspects of Cayman Islands company law dated the date hereof being on display as described in the Prospectus.

Yours faithfully,



Conyers Dill & Pearman

Partners: Piers J. Alexander, Christopher W. H. Bickley, Peter H. Y. Ch'ng, Anna W. T. Chong, Angie Y. Y. Chu, Vivien C. S. Fung, Richard J. Hall, Norman Hau, Wynne Lau, Paul M. L. Lim, Anna W. X. Lin, Michael J. Makridakis, Teresa F. Tsai, Flora K. Y. Wong, Lillian S. C. Woo, Mark P. Yeadon

Consultant: David M. Lamb

BERMUDA | BRITISH VIRGIN ISLANDS | CAYMAN ISLANDS

Date: December 13, 2022

OrbusNeich Medical Group Holdings Limited

業聚醫療集團控股有限公司

Units 303 & 305

3/F, Building 20E

Hong Kong Science Park

Shatin, N.T.

Hong Kong

Attention: The Board of Directors

Dear Sirs,

Consent to the issue of the Prospectus of OrbusNeich Medical Group Holdings Limited
業聚醫療集團控股有限公司 (the “Company”)


We refer to the prospectus of the Company dated December 13, 2022 (the “Prospectus”) in connection with the global offering and the proposed listing of the shares of the Company on the Main Board of The Stock Exchange of Hong Kong Limited (the “Stock Exchange”).

We hereby give, and confirm we have not withdrawn, our consent to the issue of the Prospectus and the inclusion therein of, and all references thereto, our name, qualification, and our market research report, in the form and context in which they respectively appear in the Prospectus.


We hereby consent to you releasing this letter to the Registrar of Companies in Hong Kong and the Stock Exchange for the purpose of the registration of the Prospectus and referring to it in the Prospectus. We also hereby consent to a copy of this letter and our market research report referred in the above being on display as described in the Prospectus.

Yours faithfully,

For and on behalf of
China Insights Industry Consultancy Limited



Name: Sophia Wang
Title: Partner



HERBERT
SMITH
FREEHILLS

OrbusNeich Medical Group Holdings Limited
業聚醫療集團控股有限公司
Unit 303 & 305
3/F, Building 20E
Hong Kong Science Park
Shatin, N.T.
Hong Kong

23rd Floor Gloucester Tower
15 Queen's Road Central
Hong Kong
T +852 2845 6639
F +852 2845 9099

www.herbertsmithfreehills.com

For the attention of The Board of Directors

Our ref
13238/31044481

Date
December 13, 2022

Dear Sirs,

Consent to the issue of the Prospectus of OrbusNeich Medical Group Holdings Limited
業聚醫療集團控股有限公司 (the "Company")

We refer to the prospectus of the Company dated ~~December 13, 2021~~ (the "Prospectus") in connection with the global offering and the proposed listing of the shares of the Company on the Main Board of The Stock Exchange of Hong Kong Limited (the "Stock Exchange").

We hereby give, and confirm we have not withdrawn, our consent to the issue of the Prospectus and the inclusion therein of, and all references thereto, our name, qualification, and our opinions, in the form and context in which they respectively appear in the Prospectus.

We hereby consent to you releasing this letter to the Registrar of Companies in Hong Kong and the Stock Exchange for the purpose of the registration of the Prospectus and referring to it in the Prospectus. We also hereby consent to a copy of this letter and our opinion being on display as described in the Prospectus.

Yours faithfully,

For and on behalf of
Herbert Smith Freehills

Name: Rachael Shek
Title: Partner

**Chief Executive Officer
and Partner**

J J G D'Agostino, MH

Managing Partners

M F Tai (Asia)
M C Emsley (China)

**Partner, Regional Head of Practice -
Disputes**

S J Chapman KC ^

A R W Aitken
H E Cassidy
J M Copeman +
A J Crockett
C K J Fan

W W H Ku
H H S Lau
A M W Z Luke
K S H Sanger
R M K Shek

Z Shen
J Sung
G H Thomas
T C P Tong
K A Wombolt

**Senior Registered
Foreign Lawyers:**
J Kong #
Y Mao #

Senior Consultants:
T A Lumsdaine
W C C Ng

**Registered Foreign
Lawyers:**
L A Lin #

^ King's Counsel, England and Wales
+ Not resident in Hong Kong

Admitted in New York (USA)

Date: December 13, 2022

OrbusNeich Medical Group Holdings Limited

業聚醫療集團控股有限公司

Units 303 & 305

3/F, Building 20E

Hong Kong Science Park

Shatin, N.T.

Hong Kong

Attention: The Board of Directors

Dear Sirs,

Consent to the issue of the Prospectus of OrbusNeich Medical Group Holdings Limited

業聚醫療集團控股有限公司 (the “Company”)

We refer to the prospectus of the Company dated December 13, 2022 (the “**Prospectus**”) in connection with the global offering and the proposed listing of the shares of the Company on the Main Board of The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

We hereby give, and confirm we have not withdrawn, our consent to the issue of the Prospectus and the inclusion therein of, and all references thereto, our name, qualification, and our opinions, in the form and context in which they respectively appear in the Prospectus.

We hereby consent to you releasing this letter to the Registrar of Companies in Hong Kong and the Stock Exchange for the purpose of the registration of the Prospectus and referring to it in the Prospectus. We also hereby consent to a copy of this letter and our opinion being on display as described in the Prospectus.

Stibbe

Amsterdam

Brussels


London

Luxembourg

New York

Yours faithfully,

For and on behalf of
Stibbe



Muriel Rosing
Partner